A phase i clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Flavonoids
  • Piperidines
  • Protein Kinase Inhibitors

abstract

  • Treatment with flavopiridol and FOLFIRI is a safe and effective regimen. Concentrations of flavopiridol that enhance the effects of FOLFIRI can be achieved. Clinical activity is encouraging and includes prolonged stable disease in patients with irinotecan-refractory colorectal cancer.

publication date

  • November 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2957673

Digital Object Identifier (DOI)

  • 10.1007/s00280-010-1269-1

PubMed ID

  • 20953860

Additional Document Info

start page

  • 1113

end page

  • 21

volume

  • 66

number

  • 6